bpc-157 fda warning news 2025 october The FDA's Pharmacy Compounding Advisory Committee is scheduled to meet Thursday and Friday to review some of the controversial, popular peptide injections and discuss whether compounding pharmacies should be able to dispense FDA panel supports access to
FDA panel supports access to peptides over scientist objections FDA's Overreach on Compounded Peptides FDA moves toward easing restrictions on certain peptides BioPharma Dive Compounded "semaglutide" is not FDA approved semaglutide.com Cytoprotection as a Unifying Strategy for Hemorrhage and Thrombosis: The Role of BPC 157 and Related Therapeutics On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Warning Letter to Platinum Biologics LLC for marketing umbilicalcordderived products including exosome products (NanoEx & Nano Xsomes) without approval.
Pay in 4 interest-free payments of $7.16 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4


